Seeing the Future: A Review of Ocular Therapy

被引:13
作者
Whalen, Maiya [1 ]
Akula, Monica [2 ]
McNamee, Shannon M. [2 ]
Deangelis, Margaret M. [3 ]
Haider, Neena B. [2 ,4 ]
机构
[1] Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA
[2] Shifa Precis, Boston, MA 02138 USA
[3] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Ophthalmol, Buffalo, NY 14203 USA
[4] Harvard Med Sch, Dept Cell Biol, Boston, MA 02138 USA
来源
BIOENGINEERING-BASEL | 2024年 / 11卷 / 02期
关键词
ocular therapy; gene therapy; cell therapy; retinal prosthesis; nanoparticles;
D O I
10.3390/bioengineering11020179
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Ocular diseases present a unique challenge and opportunity for therapeutic development. The eye has distinct advantages as a therapy target given its accessibility, compartmentalization, immune privilege, and size. Various methodologies for therapeutic delivery in ocular diseases are under investigation that impact long-term efficacy, toxicity, invasiveness, and delivery range. While gene, cell, and antibody therapy and nanoparticle delivery directly treat regions that have been damaged by disease, they can be limited in the duration of the therapeutic delivery and have a focal effect. In contrast, contact lenses and ocular implants can more effectively achieve sustained and widespread delivery of therapies; however, they can increase dilution of therapeutics, which may result in reduced effectiveness. Current therapies either offer a sustained release or a broad therapeutic effect, and future directions should aim toward achieving both. This review discusses current ocular therapy delivery systems and their applications, mechanisms for delivering therapeutic products to ocular tissues, advantages and challenges associated with each delivery system, current approved therapies, and clinical trials. Future directions for the improvement in existing ocular therapies include combination therapies, such as combined cell and gene therapies, as well as AI-driven devices, such as cortical implants that directly transmit visual information to the cortex.
引用
收藏
页数:40
相关论文
共 229 条
[1]   In vivo and in vitro toxicity evaluation of liposome-encapsulated sirolimus [J].
Abud, Murilo Batista ;
Louzada, Ricardo Noguera ;
Cruvinel Isaac, David Leonardo ;
Souza, Leonardo Gomes ;
dos Reis, Ricardo Gomes ;
Lima, Eliana Martins ;
de Avila, Marcos Pereira .
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS, 2019, 5 (01)
[2]   Gene therapy restores vision in a canine model of childhood blindness [J].
Acland, GM ;
Aguirre, GD ;
Ray, J ;
Zhang, Q ;
Aleman, TS ;
Cideciyan, AV ;
Pearce-Kelling, SE ;
Anand, V ;
Zeng, Y ;
Maguire, AM ;
Jacobson, SG ;
Hauswirth, WW ;
Bennett, J .
NATURE GENETICS, 2001, 28 (01) :92-95
[3]   CRISPR/Cas9-A Promising Therapeutic Tool to Cure Blindness: Current Scenario and Future Prospects [J].
Ahmad, Irshad .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
[4]  
Akpek Esen K, 2015, Trans Am Ophthalmol Soc, V113, pT3
[5]  
Aleman Tomas S, 2022, Ophthalmology, V129, P1177, DOI 10.1016/j.ophtha.2022.06.006
[6]   Considerations for Polymers Used in Ocular Drug Delivery [J].
Allyn, Megan M. ;
Luo, Richard H. ;
Hellwarth, Elle B. ;
Swindle-Reilly, Katelyn E. .
FRONTIERS IN MEDICINE, 2022, 8
[7]   The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited [J].
Anderson, Don H. ;
Radeke, Monte J. ;
Gallo, Natasha B. ;
Chapin, Ethan A. ;
Johnson, Patrick T. ;
Curletti, Christy R. ;
Hancox, Lisa S. ;
Hu, Jane ;
Ebright, Jessica N. ;
Malek, Goldis ;
Hauser, Michael A. ;
Rickman, Catherine Bowes ;
Bok, Dean ;
Hageman, Gregory S. ;
Johnson, Lincoln V. .
PROGRESS IN RETINAL AND EYE RESEARCH, 2010, 29 (02) :95-112
[8]  
[Anonymous], VISION IMPAIRMENT BL
[9]  
[Anonymous], RETNET SUMMARIES
[10]   Lentiviral Vectors for Ocular Gene Therapy [J].
Arsenijevic, Yvan ;
Berger, Adeline ;
Udry, Florian ;
Kostic, Corinne .
PHARMACEUTICS, 2022, 14 (08)